SCHEMBL31289

SCHEMBL31289

O=C(O)c1cccc(F)c1CCO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.53
CES2 O00748 3/20 0.42
CES1 P23141 3/20 0.42
BCHE P06276 1/20 0.42
HMGB1 P09429 1/20 0.42
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 2/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
PTPN1 P18031 2/20 0.40
ACMSD Q8TDX5 1/20 0.40
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
KDM4E B2RXH2 2/20 0.39
FOLH1 Q04609 1/20 0.38
TTR P02766 1/20 0.38
HNF4A P41235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9156347 0.86 ALDH1A1 (0.50) ALBHMGB1ALDH1A1ALOX15HPGD
Ethane SCHEMBL27714039 0.82 ALDH1A1 (0.46) ALBHMGB1ALDH1A1ALOX15HPGD
SCHEMBL16429101 0.82 ALB (0.59) ALBCES2CES1BCHEHMGB1
SCHEMBL3656083 0.81 ALB (0.57) ALBCES2CES1BCHEHMGB1
SCHEMBL16559363 0.81 ALB (0.49) ALBCES2CES1HMGB1ALDH1A1
SCHEMBL9045392 0.81 ALB (0.49) ALBCES2CES1BCHEHMGB1
SCHEMBL11022259 0.80 ALB (0.47) ALBCES2CES1BCHEHMGB1
SCHEMBL249134 0.80 TAAR1 (0.45) CES2CES1BCHEALDH1A1LMNA
SCHEMBL28130667 0.79 PTPN1 (0.50) ALBHMGB1ALDH1A1ALOX15HPGD
SCHEMBL4238085 0.79 ALB (0.55) ALBCES2CES1BCHEHMGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
EP-2406240-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2015-12-23 EP disclosed
EP-2406240-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2015-12-23 EP disclosed
US-9212153-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2015-12-15 US disclosed
US-9212153-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2015-12-15 US disclosed
EP-2801570-A1 Inhibitors of beta-secretase Vitae Pharmaceuticals, Inc. (US) 2014-11-12 EP disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 US disclosed
CN-102348698-A Inhibitors of beta-secretase VITAE PHARMACEUTICALS INC 2012-02-08 CN disclosed
EP-2406240-A2 INHIBITORS OF BETA-SECRETASE Vitae Pharmaceuticals, Inc. (US) 2012-01-18 EP disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 WO disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336717-B2 Inhibitors of beta-secretase BACE1, BACE2, PSEN1 ALB 4694/4885CES2 943/4885CES1 361/4885
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 ALB 4694/4885CES2 943/4885CES1 361/4885
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 ALB 4694/4885CES2 943/4885CES1 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.